MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00259-025-07569-5

Медицинская библиотека · European journal of nuclear medicine and molecular imaging · 2025

Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma.

Lommen Marie, Weindler Jasmin J, Jablonski Janina, Rosenbrock Johannes, Borchmann Peter, Behringer Karolin, Roth Katrin S, Ufton Dominic, Dietlein Markus, Kobe Carsten, Ferdinandus Justin

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Staging with [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET) is standard of care in classic Hodgkin lymphoma (cHL). Metabolic tumor volume (MTV) is a quantitative biomarker of tumor burden and has been shown to predict treatment response. This study investigates the association between MTV at baseline PET and health-related quality of life (HRQoL) across different disease stages.

METHODS

This post-hoc analysis included 441 patients with newly diagnosed cHL and available baseline PET imaging, enrolled in the GHSG trials HD16, HD17, and HD18. MTV was quantified using a fixed threshold of SUV ≥ 4.0 (SUV4.0) via the LifeX Analytics workstation. HRQoL was assessed using the EORTC QLQ-C30 questionnaire at baseline and, for HD18 patients, again at 2-year follow-up. Multiple regression models adjusted for sex, age, and trial/stage were used for statistical analyses.

RESULTS

Higher MTV was associated with higher baseline HRQoL burden across several domains: fatigue (β = 0.14, 95% CI [0.05; 0.24]), dyspnea (β = 0.21, 95% CI [0.11; 0.30]), appetite loss (β = 0.13, 95% CI [0.03; 0.23]), and sleep disturbance (β = 0.12, 95% CI [0.02; 0.22]). In contrast, higher MTV was negatively associated with physical functioning (β = -0.18, 95% CI [-0.27; -0.08]) and global health status (β = -0.15, 95% CI [-0.25; -0.06]). The strongest associations were observed in patients with advanced-stage disease (HD18). At 2-year follow-up in HD18, no associations between MTV at baseline and HRQoL were found, with the exception of pain, which remained the only associated domain (β = 0.15, 95% CI [0.00; 0.30]).

CONCLUSION

Baseline MTV is strongly associated with HRQoL before therapy in patients with newly diagnosed cHL, particularly in those with advanced-stage disease. Reassuringly, there seems to be no major influence of initial disease burden on HRQoL within the second year of recovery.

TRIAL REGISTRATION: ClinicalTrials.gov: HD16 (NCT00736320; first posted August 15, 2008), HD17 (NCT01356680; first posted May 19, 2011), HD18 (NCT00515554; first posted August 13, 2007).

Для цитирования: Lommen Marie, Weindler Jasmin J, Jablonski Janina, Rosenbrock Johannes, Borchmann Peter, Behringer Karolin, Roth Katrin S, Ufton Dominic, Dietlein Markus, Kobe Carsten, Ferdinandus Justin. Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma.. European journal of nuclear medicine and molecular imaging. 2025. DOI: 10.1007/s00259-025-07569-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.